scholarly journals Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? results from a randomized clinical trial

2015 ◽  
Vol 18 (2) ◽  
pp. 137-144 ◽  
Author(s):  
Marijke R. Wevers ◽  
Margreet G. E. M. Ausems ◽  
Senno Verhoef ◽  
Eveline M. A. Bleiker ◽  
Daniela E. E. Hahn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Genetic Counseling ◽  
Randomized Clinical Trial ◽  
Cancer Patients ◽  
Psychosocial Distress ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Counseling And Testing

scholarly journals Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Safa Najafi ◽  
Maryam Ansari ◽  
Vahid Kaveh ◽  
Shahpar Haghighat
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Single Dose ◽  
Side Effects ◽  
Randomized Clinical Trial ◽  
Cancer Patients ◽  
Injection Site Reaction ◽  
Study Groups ◽  
Breast Cancer Patients ◽  
Significant Difference

Abstract Background The objective of this study was to compare the efficacy and side effects of a single dose (Pegfilgrastim or PDL) or repeated six daily injections (Filgrastim or PDG) during chemotherapy courses in breast cancer patients in a non-inferiority clinical trial. Methods In this randomized clinical trial, 80 patients were recruited and allocated randomly to two equal arms. In one group, a single subcutaneous dose of PDL was injected the day after receiving the chemotherapy regimen in each cycle. The second arm received a subcutaneous injection of PDG for six consecutive days in each cycle of treatment. The side effects of GCF treatment and its effect on blood parameters were compared in each cycle and during eight cycles of chemotherapy. Results Hematologic parameters showed no significant differences in any of the treatment courses between the two study groups. The comparison of WBC (p = 0.527), Hgb (p = 0.075), Platelet (p = 0.819), Neutrophil (p = 0.575), Lymphocyte (p = 705) and ANC (p = 0.675) changes during the eight courses of treatment also revealed no statistically significant difference between the two study groups. Side effects including headache, injection site reaction and muscle pain had a lower frequency in patients receiving PDL drugs. Conclusion It seems that PDL is non-inferior in efficacy and also less toxic than PDG. Since PDL can be administered in a single dose and is also less costly, it can be regarded as a cost-effective drug for the treatment of chemotherapy-induced neutropenia. Trial registration IRCT20190504043465N1, May 2019.

scholarly journals Citalopram and group psychotherapy in breast cancer patients: A randomized clinical trial

2018 ◽  
Vol 32 (1) ◽  
pp. 394-399
Author(s):  
Novin Nikbakhsh ◽  
Sussan Moudi ◽  
Sara Alvarzandi ◽  
Maede Niazifar ◽  
Nazila Farnoush ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Cancer Patients ◽  
Group Psychotherapy ◽  
Breast Cancer Patients

Study of pregabalin effect on postsurgical pain in breast cancer patients: A double‐blind randomized clinical trial using placebo

2020 ◽  
Vol 26 (11) ◽  
pp. 2286-2288
Author(s):  
Ali Mir ◽  
Niayesh Mohebbi ◽  
Ramesh Omranipour ◽  
Mojtaba Sedaghat ◽  
Marzieh Lashkari ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Double Blind ◽  
Postsurgical Pain
Sign in / Sign up

Export Citation Format

Share Document